IL181169A0 - Trifluoromethyl substituted benzamides as kinase inhibitors - Google Patents

Trifluoromethyl substituted benzamides as kinase inhibitors

Info

Publication number
IL181169A0
IL181169A0 IL181169A IL18116907A IL181169A0 IL 181169 A0 IL181169 A0 IL 181169A0 IL 181169 A IL181169 A IL 181169A IL 18116907 A IL18116907 A IL 18116907A IL 181169 A0 IL181169 A0 IL 181169A0
Authority
IL
Israel
Prior art keywords
kinase inhibitors
substituted benzamides
trifluoromethyl substituted
trifluoromethyl
benzamides
Prior art date
Application number
IL181169A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL181169A0 publication Critical patent/IL181169A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL181169A 2004-08-11 2007-02-05 Trifluoromethyl substituted benzamides as kinase inhibitors IL181169A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds
PCT/EP2005/008695 WO2006015859A1 (en) 2004-08-11 2005-08-10 Trifluoromethyl substituted benzamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
IL181169A0 true IL181169A0 (en) 2007-07-04

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181169A IL181169A0 (en) 2004-08-11 2007-02-05 Trifluoromethyl substituted benzamides as kinase inhibitors

Country Status (17)

Country Link
US (2) US20060035897A1 (enrdf_load_stackoverflow)
EP (1) EP1778640A1 (enrdf_load_stackoverflow)
JP (1) JP2008509187A (enrdf_load_stackoverflow)
KR (1) KR20070046851A (enrdf_load_stackoverflow)
CN (2) CN101696188A (enrdf_load_stackoverflow)
AU (1) AU2005270313A1 (enrdf_load_stackoverflow)
BR (1) BRPI0514288A (enrdf_load_stackoverflow)
CA (1) CA2575316A1 (enrdf_load_stackoverflow)
EC (1) ECSP077235A (enrdf_load_stackoverflow)
GB (1) GB0417905D0 (enrdf_load_stackoverflow)
IL (1) IL181169A0 (enrdf_load_stackoverflow)
MA (1) MA28822B1 (enrdf_load_stackoverflow)
MX (1) MX2007001642A (enrdf_load_stackoverflow)
NO (1) NO20071300L (enrdf_load_stackoverflow)
RU (1) RU2007108861A (enrdf_load_stackoverflow)
TN (1) TNSN07048A1 (enrdf_load_stackoverflow)
WO (1) WO2006015859A1 (enrdf_load_stackoverflow)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
WO2006118256A1 (ja) * 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
EP2606890A1 (en) * 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
EP2043638A2 (en) * 2006-07-13 2009-04-08 Novartis AG Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
ES2360927T3 (es) * 2006-09-05 2011-06-10 Amgen Inc. Compuestos de ftalazina, aza y diazaftalazina y métodos de uso.
WO2008077064A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Biomarker identifying the reactivation of stat3 after src inhibition
WO2008079965A1 (en) * 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP2152704A1 (en) * 2007-05-07 2010-02-17 Amgen, Inc Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
US8022085B2 (en) * 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
US8367671B2 (en) * 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
WO2009131173A1 (ja) 2008-04-23 2009-10-29 協和発酵キリン株式会社 2-アミノキナゾリン誘導体
WO2010025201A1 (en) 2008-08-29 2010-03-04 Amgen Inc. Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
US8420649B2 (en) 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
WO2010042649A2 (en) 2008-10-10 2010-04-15 Amgen Inc. PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
WO2010042646A1 (en) 2008-10-10 2010-04-15 Amgen Inc. Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
WO2010144394A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Benzyl substituted triazine derivatives and their therapeutical applications
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
CA2765030C (en) 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
KR20120115237A (ko) * 2009-10-30 2012-10-17 어리어드 파마슈티칼스, 인코포레이티드 암 치료 방법 및 조성물
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
US20140323519A1 (en) * 2011-04-26 2014-10-30 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
EP3097102B1 (en) 2015-03-04 2017-10-18 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
JP2008509187A (ja) 2008-03-27
BRPI0514288A (pt) 2008-06-10
MA28822B1 (fr) 2007-08-01
MX2007001642A (es) 2007-04-10
NO20071300L (no) 2007-04-19
WO2006015859A1 (en) 2006-02-16
RU2007108861A (ru) 2008-09-20
KR20070046851A (ko) 2007-05-03
EP1778640A1 (en) 2007-05-02
AU2005270313A1 (en) 2006-02-16
CN101039914A (zh) 2007-09-19
CA2575316A1 (en) 2006-02-16
US20080096883A1 (en) 2008-04-24
US20060035897A1 (en) 2006-02-16
CN101696188A (zh) 2010-04-21
ECSP077235A (es) 2007-03-29
TNSN07048A1 (en) 2008-06-02
GB0417905D0 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
IL181169A0 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
IL181811A (en) Phenylaminopyrimidines are conserved in trifluoromethyl as inhibitors of @ - @ abl - @ bcr @@ kinase
IL181720A0 (en) Bicyclic amides as kinase inhibitors
EP1794137A4 (en) SPECIFIC KINASE INHIBITORS
EP1753428A4 (en) INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
GB2424882B (en) Selective kinase inhibitors
GB0403635D0 (en) Pyridinocarboxamides with improved activity as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL183276A0 (en) Kinase inhibitors
IL179280A0 (en) Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
EP1761268A4 (en) KINASE INHIBITORS BASED ON PYRROLOTRIAZINE
ZA200608221B (en) Thiadlazolidinones as GSK-3 Inhibitors
IL190078A0 (en) Kinase inhibitors
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
EP1773837A4 (en) Pyrrolotriazine KINASE INHIBITORS
PL1943243T3 (pl) Inhibitory kinazy
EP1778693A4 (en) AS KINASEINHIBITORS USEFUL COMPOUNDS OF TRICYCLIC HETEROARYL
ZA200607648B (en) Kinase inhibitors
EP1713793A4 (en) PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
ZA200608775B (en) Monocyclic heterocycles as kinase inhibitors
ZA200700650B (en) Bicyclic amides as kinase inhibitors
PL1896422T3 (pl) Inhibitory kinazy tyrozynowej
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
HK1101689A (en) Trifluoromethyl substituted benzamides as kinase inhibitors